Articles Mentioning Life Sciences Tools and Services Stocks

Results 11 - 20 of 375 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Life Sciences Tools and Services

Investing | February 10, 2014

Europe Isn't Weighing Down Mettler-Toledo Anymore

The market for lab equipment is improving in Europe and the U.S., boosting results for Mettler Toledo.

Investing | January 27, 2014

Is Thermo Fisher Scientific Inc. Destined for Greatness?

Diagnostics leader Thermo-Fisher (TMO) could soon make a huge splash in genomics, but it's got plenty of other irons in the fire as well.

Investing | January 23, 2014

When Will the Sub-$1,000 Human Genome Arrive?

The media swarmed over Illumina's announcement of a system capable of sequencing a human genome for $1,000 in the near future, but when will the company and Thermo Fisher Scientific break that barrier on a routine basis?

Investing | January 22, 2014

2014: The Year of Personalized Medicine

After a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?

Investing | January 22, 2014

The $1,000 Genome Marks the Start of a New Phase in Human Evolution

Unlocking the "human code" makes possible all manner of changes we might have never considered before. Are we ready for what that might mean?

Investing | January 22, 2014

Why You Need to Watch Teva, AMAG, AstraZeneca, and Nektar Therapeutics This Morning

Teva Pharmaceutical, AMAG Pharmaceuticals, AstraZeneca, and Nektar Therapeutics could loom large in health-care headlines this morning. Here’s why.

Investing | January 15, 2014

3 Ways the $1,000 Human Genome Can Revolutionize Science and Medicine As We Know It

The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.

Investing | December 07, 2013

How 23andMe Can Spur Growth for These Diagnostics Companies

Direct-to-consumer genetic tests took a hit when the Food and Drug Administration told 23andMe to stop marketing its product. However, accepting the arrival of accessible genetic information could ignite growth opportunities for Myriad Genetics, Genomic Health, and Quest Diagnostics.

Investing | December 06, 2013

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

Investing | November 05, 2013

Why Did This Genetic Test Maker Outperform Its Industry Peers?

Shares of Affymetrix have been on fire over the past year despite lacking any real fundamental fuel. Will this hot stock keep rising, or is it destined to crash and burn?

Results 11 - 20 of 375 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Life Sciences Tools and Services